Unicorn Nest news
GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021
– GenEdit has closed a $26m Series A financing.
– New investors include Eli Lilly, KTB Network, Company K Partners, Korea Investment Partners, DAYLI Partners, KB Investment, IMM Investment, and TIMEFOLIO Asset Management.
– The funding will support the further development of GenEdit’s NanoGalaxy™ platform of non-viral, non-lipid polymer nanoparticles, and the selection for clinical development of therapeutic candidates targeting diseases of the nervous system.
Unicorn Nest news
Revenue-based financing startup Jenfi raises $6.3M to focus on high-growth Southeast Asian companies
– Jenfi, a Singapore-based startup, raised $6.3m in Series A funding.
– The round was led by Monk’s Hill Ventures and joined by Korea Investment Partners, Golden Equator Capital, 8VC, ICU Ventures and Taurus Ventures.
– The company previously raised $25m in debt financing from San Francisco-based Arc Labs.
– Jenfi works primarily with “digital-native” companies, including SaaS providers and e-commerce sellers.
– It claims that the average Jenfi customer experienced compounded sales growth of about 26.5% over three months, 60% over six months and 156% over 12 months.
Unicorn Nest news
S-Alpha Therapeutics, Inc., Digital Therapeutics Start-up Raises $8.7 Million in Series A Funding
– S-Alpha Therapeutics announced the completion of its Series A financing.
– The company raised a total of $8.7M USD (10 Billion KRW) in financing round.
– In Series A funding, all existing investors participated in this investment, and Korea Investment Partners, Stonebridge Ventures, Devsisters Ventures/KDB Capital, and Timewise Investment participated as new investors.
Unicorn Nest news
Eyevensys Raises $12M in a Series B Plus Funding Round
– Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, announces it has raised $12M in a Series B Plus funding round.
– Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round.
– The financing will support Eyevensys’ accelerated development of its EYS809 program for the treatment of wet age-related macular degeneration (AMD), a chronic eye disorder that causes blurred vision or a blind spot in the eye. The condition accounts for approximately 90 percent of all AMD-related blindness. Additionally, the company will advance its EYS611 program targeting geographic atrophy (GA) and retinitis pigmentosa.
Unicorn Nest news
Geneos Therapeutics Raises $12M in Series A1 Financing
– Geneos Therapeutics from Plymouth Meeting, Pa. develops personalized neoantigen-targeting immunotherapies for cancer.
– The company raised $12m in Series A1 funding.
– The round was led by Korea Investment Partners (KIP) – Global Bio Fund with participation from existing investors Santé Ventures and Inovio Pharmaceuticals, Inc. (NASDAQ: INO).
– The company plans to use the funds for the expansion of the company’s:
– GT-30 Phase Ib/IIa clinical trial evaluating its personalized neoantigen-targeting vaccine,